<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299195</url>
  </required_header>
  <id_info>
    <org_study_id>04-099</org_study_id>
    <nct_id>NCT00299195</nct_id>
  </id_info>
  <brief_title>A Randomized Study of Sulindac in Oral Premalignant Lesions</brief_title>
  <official_title>A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amrita Institute of Sciences, AIMS, Cochin, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Cancer Center(RCC), Trivandrum, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Narayana Hrudayalaya Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a drug called sulindac can prevent the development of&#xD;
      changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia)&#xD;
      or oral cancer. Sulindac is an anti-inflammatory drug that has already been tested in people&#xD;
      with arthritis (inflammation of a joint).&#xD;
&#xD;
      This study is being done by Memorial Sloan-Kettering Cancer Center in New York, Amrita&#xD;
      Institute of Medical Sciences and Research Center in Cochin, India, and Regional Cancer&#xD;
      Centre (RCC) in Trivandrum, India.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral precancerous lesions (OPL) represent a valuable model for clinical trials for tobacco&#xD;
      related cancers. However, due to the relatively low prevalence of this condition in the&#xD;
      United States, subject accrual to such trials is slow. Conversely, in India, the prevalence&#xD;
      of oral leukoplakia is among the highest in the world. Indeed oral cancer, caused by exposure&#xD;
      to tobacco smoke, alcohol and betel nut quid, is the leading cause of cancer deaths in India.&#xD;
&#xD;
      To date, there are no effective treatments documented in randomized controlled clinical&#xD;
      trials to prevent malignant transformation of leukoplakia. However, evidence that&#xD;
      non-steroidal anti-inflammatory drugs (NSAIDs) prevent experimental and animal head and neck&#xD;
      cancer, and colon and breast cancer in humans lends support to the promise of NSAIDs in the&#xD;
      chemoprevention of oral cancer.&#xD;
&#xD;
      The purpose of this protocol is to pilot a multi-center chemoprevention trial of sulindac, a&#xD;
      pan-cyclooxygenase (COX) inhibitor, for oral leukoplakia through an international&#xD;
      collaboration between Memorial Sloan-Kettering Cancer Center (MSKCC), New York, Regional&#xD;
      Cancer Centre (RCC) in Trivandrum, India and the Amrita Institute of Medical Sciences (AIMS),&#xD;
      Kerala, India. Specifically, we will conduct a 66 subject, 2-arm, double-blind,&#xD;
      placebo-controlled randomized study of sulindac 150 mg bid to test the clinical efficacy,&#xD;
      safety and molecular effects of sulindac against OPL and OPL tissue. Oral leukoplakia&#xD;
      subjects will be enrolled from both RCC, AIMS and MSKCC, however, we expect that most&#xD;
      subjects will be recruited from AIMS due to the substantially higher prevalence of this&#xD;
      condition among the Indian compared to the US population.&#xD;
&#xD;
      MSKCC will be the coordinating center for this trial, and will thus be responsible for all&#xD;
      aspects of clinical trial design and management. Our study team, in collaboration with the&#xD;
      Office of Clinical Research and the Office of the Physician-in-Chief, has spent a&#xD;
      considerable amount of time and effort in developing a comprehensive data and safety&#xD;
      monitoring (DSM) plan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2006</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">January 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To Evaluate the Efficacy of Sulindac in Subjects With Early or Advanced Oral Premalignant Lesion (OPL) by Both Clinical Response (Reduction in Size of All Lesions) and Histological Response (Change in Histological Grade).</measure>
    <time_frame>after 24 weeks of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Effect of Sulindac in Modulating the Expression of the Intermediate Biomarkers Ki67, p53 Proteins and DNA Ploidy After 24 Weeks of Treatment of Study Drug, and Again After 8 Weeks Off Study Drug.</measure>
    <time_frame>after 24 weeks of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Correlation Between Baseline COX-2 Expression or DNA Ploidy With Clinical Response or Biomarker Modulation</measure>
    <time_frame>baseline and after 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Safety of Chronic Dosing of Sulindac in This Subject Population</measure>
    <time_frame>week 4, 8, 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Explore the Relationship Between Genetic Polymorphisms of Genes Involved in Carcinogenesis and Clinical or Biomarker Response to Sulindac</measure>
    <time_frame>after 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Leukoplakia, Oral</condition>
  <condition>Benign Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sulindac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulindac</intervention_name>
    <description>Sulindac 150 mg po bid x 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo bid x 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For this study an Oral Premalignant Lesions (OPL) is defined as a lesion which can include&#xD;
        atypical hyperplasia, atypical hyperkeratosis, leukoplakia, and&#xD;
        erythroplakia/erythro-leukoplakia. Histology MUST be confirmed by an MSKCC pathologist for&#xD;
        all participating sites. An OPL may be located in the oral cavity, oropharynx.&#xD;
&#xD;
          -  The subj has a histologically suspected or confirmed index oral premalignant lesion,&#xD;
             12mm or greater in size that has not been bx'd in the past 6 wks. Each index lesion&#xD;
             must be either:&#xD;
&#xD;
               -  An EARLY premalignant lesion defined to be at high risk as indicated by the&#xD;
                  presence of at least one of the following: atypical cells or mild dysplasia, or&#xD;
                  hyperplastic leukoplakia of high-risk sites, lateral and ventral tongue and floor&#xD;
                  or mouth OR&#xD;
&#xD;
               -  An ADVANCED premalignant lesion defined as the presence of at least one of the&#xD;
                  following: moderate dysplasia or severe dysplasia (excluding CIS)&#xD;
&#xD;
          -  The subj is &gt; 18 yrs of age&#xD;
&#xD;
          -  The subj's life expectancy is &gt; 12 wks and Zubrod performance status is 0 or 1&#xD;
             (Appendix VIII).&#xD;
&#xD;
          -  The subj meets the following lab eligibility criteria during a time not to exceed 4&#xD;
             wks prior to randomization.&#xD;
&#xD;
               -  Hemoglobin level above 10g/dL for women and above 12g/dL for men.&#xD;
&#xD;
               -  WBC count &gt; 3,000 uL.&#xD;
&#xD;
               -  Platelets count &gt; 125,000 uL.&#xD;
&#xD;
               -  Total bilirubin &lt; or = 1.5xULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) &lt; or = 2.5 x ULN.&#xD;
&#xD;
               -  BUN and serum creatinine &lt; or = 1.5 x ULN.&#xD;
&#xD;
          -  If the subj is female and of childbearing potential (women are considered not of&#xD;
             childbearing potential if they are at least 2 yrs postmenopausal and/or surgically&#xD;
             sterile), she:&#xD;
&#xD;
               -  has been using adequate contraception (abstinence, IUD, birth control pills, or&#xD;
                  spermicidal gel with diaphragm or condom) since her last menses and will use&#xD;
                  adequate contraception during the study, AND&#xD;
&#xD;
               -  is not lactating, AND&#xD;
&#xD;
               -  has a documented negative serum pregnancy test within 14 ds prior to&#xD;
                  randomization.&#xD;
&#xD;
          -  The subj's history/use of NSAIDs, aspirin, corticosteroids meets the following&#xD;
             criteria:&#xD;
&#xD;
               -  total oral/intravenous corticosteroid use has been &lt; 14 ds within 6 mos of the&#xD;
                  Baseline visit, and&#xD;
&#xD;
               -  total inhaled corticosteroid use has been &lt; 30 ds within 6 mos of the Baseline&#xD;
                  visit, and&#xD;
&#xD;
               -  is willing to limit aspirin use to &lt; or = 120 mg po per d (typical&#xD;
                  cardioprotective dose in India) or &lt; or = 80 mg po per d (typical&#xD;
                  cardioprotective dose in the US) for the duration of the study, and is willing to&#xD;
                  abstain from chronic use of all NSAIDs and COX-2 inhibitors for duration of&#xD;
                  study. Chronic use of NSAIDs is defined as a frequency of &gt; or = 3 times/wk AND&#xD;
                  for more than a total of 14 ds a yr.&#xD;
&#xD;
          -  The subj has discontinued any other chemopreventive therapy at least 3 mos prior to&#xD;
             the Baseline visit and all toxicities have been fully resolved.&#xD;
&#xD;
          -  If applicable, the subj has been counseled on smoking cessation.&#xD;
&#xD;
          -  If the subject is male, will use adequate contraception during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has had chemotherapy, immunotherapy, hormonal tx (other than HRT for&#xD;
             menopause), or RT within 3 wks of the Baseline visit.&#xD;
&#xD;
          -  The subj has not recovered from the acute toxic effects of chemotherapy,&#xD;
             immunotherapy, hormonal tx, or RT.&#xD;
&#xD;
          -  The subj will need concurrent chemotherapy, radiotherapy, hormonal (other than HRT for&#xD;
             menopause), or immunotherapy during the time of study.&#xD;
&#xD;
          -  The subj has a history of hypersensitivity to sulindac, COX-2 inhibitors, NSAIDs,&#xD;
             salicylates.&#xD;
&#xD;
          -  The subj has been diagnosed with or has been treated for esophageal, gastric, pyloric&#xD;
             channel, or duodenal ulceration.&#xD;
&#xD;
          -  The subj has a history of inv cancer within the past 1 yr (excluding non-melanoma skin&#xD;
             cancer and in situ cervical cancer).&#xD;
&#xD;
          -  The subj has a chronic or acute renal or hepatic disorder or a significant bleeding&#xD;
             disorder or any other condition which, in the Institutional Principal Investigator's&#xD;
             opinion, might preclude study participation.&#xD;
&#xD;
          -  The subj has a past history of or active inflammatory bowel disease (eg. Crohn's&#xD;
             disease or ulcerative colitis) or pancreatic disease.&#xD;
&#xD;
          -  The subj has received any investigational medication within 30 ds of the Baseline&#xD;
             visit or is scheduled to receive an investigational drug during the course of the&#xD;
             study.&#xD;
&#xD;
          -  The subj is, in the opinion of the Institutional Principal Investigator, not an&#xD;
             appropriate candidate for study participation.&#xD;
&#xD;
          -  The subj participated in the study previously and was withdrawn.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay O. Boyle, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Sciences (AIMS)</name>
      <address>
        <city>Cochin</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center (RCC)</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2006</study_first_posted>
  <results_first_submitted>October 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Leukoplakia</keyword>
  <keyword>Benign Neoplasms</keyword>
  <keyword>Chemoprevention</keyword>
  <keyword>Pan-cyclooxygenase (COX) inhibitor</keyword>
  <keyword>sulindac</keyword>
  <keyword>04-099</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Leukoplakia, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT00299195/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" lower_limit="32" upper_limit="84"/>
                    <measurement group_id="B2" value="58.6" lower_limit="28" upper_limit="84"/>
                    <measurement group_id="B3" value="56.6" lower_limit="28" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>- To Evaluate the Efficacy of Sulindac in Subjects With Early or Advanced Oral Premalignant Lesion (OPL) by Both Clinical Response (Reduction in Size of All Lesions) and Histological Response (Change in Histological Grade).</title>
        <time_frame>after 24 weeks of study drug</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>- To Evaluate the Efficacy of Sulindac in Subjects With Early or Advanced Oral Premalignant Lesion (OPL) by Both Clinical Response (Reduction in Size of All Lesions) and Histological Response (Change in Histological Grade).</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Effect of Sulindac in Modulating the Expression of the Intermediate Biomarkers Ki67, p53 Proteins and DNA Ploidy After 24 Weeks of Treatment of Study Drug, and Again After 8 Weeks Off Study Drug.</title>
        <time_frame>after 24 weeks of study drug</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Effect of Sulindac in Modulating the Expression of the Intermediate Biomarkers Ki67, p53 Proteins and DNA Ploidy After 24 Weeks of Treatment of Study Drug, and Again After 8 Weeks Off Study Drug.</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Correlation Between Baseline COX-2 Expression or DNA Ploidy With Clinical Response or Biomarker Modulation</title>
        <time_frame>baseline and after 24 weeks</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Correlation Between Baseline COX-2 Expression or DNA Ploidy With Clinical Response or Biomarker Modulation</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Safety of Chronic Dosing of Sulindac in This Subject Population</title>
        <time_frame>week 4, 8, 12, 16, 20 and 24</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Safety of Chronic Dosing of Sulindac in This Subject Population</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Explore the Relationship Between Genetic Polymorphisms of Genes Involved in Carcinogenesis and Clinical or Biomarker Response to Sulindac</title>
        <time_frame>after 24 weeks</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Explore the Relationship Between Genetic Polymorphisms of Genes Involved in Carcinogenesis and Clinical or Biomarker Response to Sulindac</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>sulindac&#xD;
sulindac: Sulindac 150 mg po bid x 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>placebo&#xD;
Placebo: Placebo bid x 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not assoc w CTCAE term- Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine, other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other (specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gastritis (incl bile reflux gastritis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Inf norm ANC/gr1/2 neut-Gingivitis(oral-gums)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Mucositis (Clin exam)- Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Other (specify)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphatics - Other (specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/Bleeding, other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inf norm ANC/gr1/2 neut-Bronchitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pulm/upp respiratory - Other (spec)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jay Boyle, MD</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-2906</phone>
      <email>boylej@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

